Related Experiment Video
Updated: Jun 3, 2025
Author Spotlight: Investigating Immune Cell Dynamics in the Tumor Microenvironment — Challenges and Innovations in Cancer Prognosis
Published on: April 12, 2024
Targeting Cancer: Microenvironment and Immunotherapy Innovations
Irena Barbara Padzińska-Pruszyńska1, Bartłomiej Taciak1, Łukasz Kiraga2
1Center of Cellular Immunotherapies, Warsaw University of Life Sciences, 02-787 Warsaw, Poland.
Abstract:
In 2024, the United States was projected to experience 2 million new cancer diagnoses and approximately 611,720 cancer-related deaths, reflecting a broader global trend in which cancer cases are anticipated to exceed 35 million by 2050. This increasing burden highlights ongoing challenges in cancer treatment despite significant advances that have reduced cancer mortality by 31% since 1991. Key obstacles include the disease's inherent heterogeneity and complexity, such as treatment resistance, cancer stem cells, and the multifaceted tumor microenvironment (TME). The TME-comprising various tumor and immune cells, blood vessels, and biochemical factors-plays a crucial role in tumor growth and resistance to therapies. Recent innovations in cancer treatment, particularly in the field of immuno-oncology, have leveraged insights into TME interactions. An emerging example is the FDA-approved therapy using tumor-infiltrating lymphocytes (TILs), demonstrating the potential of cell-based approaches in solid tumors. However, TIL therapy is just one of many strategies being explored. This review provides a comprehensive overview of the emerging field of immuno-oncology, focusing on how novel therapies targeting or harnessing components of the TME could enhance treatment efficacy and address persistent challenges in cancer care.
Insights
Cancer treatment faces challenges from tumor complexity and resistance. Novel immuno-oncology strategies targeting the tumor microenvironment (TME) show promise for improving patient outcomes.
Area of Science:
- Oncology
- Immunology
- Cancer Biology
Background:
- Cancer presents a growing global health challenge, with millions of new cases and deaths projected annually.
- Despite progress, cancer treatment faces hurdles including tumor heterogeneity, treatment resistance, cancer stem cells, and the tumor microenvironment (TME).
- The TME significantly influences tumor progression and therapeutic resistance.
Purpose of the Study:
- To provide a comprehensive review of immuno-oncology.
- To highlight novel therapeutic strategies targeting the TME.
- To discuss how these strategies can overcome treatment resistance and improve efficacy.
Main Methods:
- Literature review of immuno-oncology and TME-targeting therapies.
- Analysis of recent advancements, including cell-based therapies like tumor-infiltrating lymphocytes (TILs).
- Discussion of the role of the TME in cancer progression and treatment response.
Main Results:
- Immuno-oncology has emerged as a key area in cancer treatment innovation.
- Targeting the TME offers a promising avenue to enhance current therapies.
- Cellular therapies, such as TILs, demonstrate potential in treating solid tumors.
Conclusions:
- Novel immuno-oncology approaches targeting the TME are crucial for advancing cancer care.
- Harnessing the TME can potentially overcome treatment resistance and improve outcomes.
- Further research into TME-modulating therapies is warranted to address persistent challenges in oncology.
More Related Videos
07:55Flow Cytometry-Based Isolation and Therapeutic Evaluation of Tumor-Infiltrating Lymphocytes in a Mouse Model of Pancreatic Cancer
Published on: January 17, 2025
07:46Microfluidic Co-Culture Models for Dissecting the Immune Response in in vitro Tumor Microenvironments
Published on: April 30, 2021
Related Concept Videos
01:27Tumor Immunotherapy
02:17The Tumor Microenvironment
01:30Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...